Next Article in Journal
Predictive Risk Factors of Nonalcoholic Fatty Liver Disease in a Lean Chinese Population
Previous Article in Journal
Factors Predicting Outcomes of Supine Percutaneous Nephrolithotomy: Large Single-Centre Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 12
Issue 12
10.3390/jpm12121957
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis

by
Joo Hyun Oh
1,†,
Dong Ah Park
2,†,
Min Jung Ko
2,
Jeong-Ju Yoo
3,
Sun Young Yim
4,
Ji-Hyun Ahn
5,
Dae Won Jun
6,* and
Sang Bong Ahn
1,*
1
Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul 01830, Republic of Korea
2
Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul 04933, Republic of Korea
3
Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea
4
Department of Internal Medicine, Korea University Hospital, Seoul 02841, Republic of Korea
5
Department of Internal Medicine, Hanyang University College of Medicine, Guri 11923, Republic of Korea
6
Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Pers. Med. 2022, 12(12), 1957; https://doi.org/10.3390/jpm12121957
Submission received: 8 October 2022 / Revised: 8 November 2022 / Accepted: 22 November 2022 / Published: 26 November 2022
Browse Figures
Versions Notes

Abstract

:
Hepatitis B (HBV) reactivation was observed to be more than 10% in patients receiving interferon-based therapy for hepatitis C (HCV) co-infection. At present, when direct-acting antiviral (DAA) has become the main treatment for HCV, there are few large-scale studies on the reactivation of HBV in these population. We studied HBV reactivation risk and prophylactic HBV treatment efficacy in HBV/HCV co-infected patients receiving DAA therapy. Relevant studies were selected from the Ovid-Medline, Ovid-EMBASE, Cochrane Central Register of Controlled Trials, KoreaMed, KMbase, and RISS databases through 4 September 2020. Data pooling was carried out using the random-effects method. We identified 39 articles with 119,484 patients with chronic (n = 1673) or resolved (n = 13,497) HBV infection under DAA therapy. When the studies were pooled, the HBV reactivation rate was 12% (95% confidence interval (CI) 6–19, I2 = 87%), indicating that this population needs careful attention. When stratified by baseline HBV DNA, the undetectable HBV DNA group showed a significantly lower risk of reactivation than the detectable HBV DNA group (odds ratio (OR) 0.30, 95% CI 0.11–0.86, I2 = 0%). Prophylactic HBV therapy reduced HBV reactivation risk (OR 0.25, 95% CI 0.07–0.92, I2 = 0%). Patients with a resolved HBV infection showed a negligible rate (0.4%) of HBV reactivation. In conclusion, patients with detectable HBV DNA levels warrant careful monitoring for HBV reactivation and may benefit from preventive anti-HBV treatment.

1. Introduction

Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection is the leading cause of chronic liver disease worldwide. Since the two viruses have common transmission pathways, from 1.5% to 14% patients living in endemic areas can be infected with both HBV and HCV [1]. Patients with HBV/HCV co-infection have more severe inflammation and fibrosis and a higher risk of cirrhosis than those with a mono-infection [2]. Furthermore, HBV and HCV co-infection synergistically affect the development of HCC [3]. Patients with HBV or HCV should, thus, be evaluated for co-infection and treated appropriately if co-infection is detected [4,5]. As HCV is usually dominant over HBV, co-infected patients are often treated like those with HCV mono-infection [6].
Previously, interferon-based therapy was the standard of care for HCV patients. Interferon also shown favorable results in HBV patients, with 5–10% of interferon-treated patients achieving HBsAg seroconversion [7]. However, HBV/HCV co-infected patients had undesirable results that HBV-infected patients, with from 19.1% to 36.4% of patients developing HBV reactivation following interferon-based treatment [8]. This phenomenon might be because treatment with HCV alters the activity of HBV. At present, with a better understanding of the HCV genome and proteins, direct-acting antiviral (DAA) therapies have been developed, resulting in significant improvements in the effectiveness, safety, and tolerability of HCV therapies. Unfortunately, there are increasing concerns regarding HBV reactivation following DAAs therapy among patients with HCV and concurrent HBV infection. According to the US Food and Drug Administration, 2 out of 24 HBV/HCV co-infected patients treated with DAAs died, and 1 required liver transplantation due to HBV reactivation between November 2013 and July 2016 [9]. Recently, DAA-induced HBV reactivation has been reported in several studies. Chen et al. described that the risk of HBV reactivation in co-infected patients was estimated at 12.2% [10]. Another recent randomized trial showed that HBV reactivation occurred in 50% of patients, and entecavir prophylaxis significantly lowered the rate of reactivation [11].
Since reactivation rates vary across studies, a comprehensive review and meta-analysis are required. In addition, it is unclear which factors increase the chance of reactivation and the need for pre-emptive antiviral therapy. To address this issue, we performed a meta-analysis to estimate the risk of HBV reactivation in patients with HBV/HCV co-infection receiving DAA treatment.

2. Materials and Methods

2.1. Data Search Strategy

We searched Ovid-medline, Ovid-EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), KoreaMed, KMbase, and RISS databases from their inception to September 2020 using the following search terms and their variations: hepatitis B virus, AND hepatitis C virus, DAA, and HBV reactivation (Supplementary Table S1). The data search was limited to English- or Korean-language articlesThe protocol for this review was registered in advance in the PROSPERO register (International Prospective Register of Systematic Reviews (CRD42021241245). The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) checklist.

2.2. Study Selection

Patients were eligible if they had both chronic HCV infection treated with DAAs and active (HBsAg (+)) or resolved (HBsAg (−) but HBcAb (+)) HBV infection. Studies were included if they met the following inclusion criteria: (1) studies evaluated in patients with HBV/HCV co-infection, (2) studies using DAA, and (3) studies reporting HBV reactivation. Articles were excluded for the following reasons: (1) non-human or pre-clinical studies; (2) reviews or meta-analyses, guidelines, consensus, comments, or letters; (3) non-Korean or non-English language; and (4) absence of detailed data. Since the first DAAs were approved by the FDA in 2011, we also excluded studies published before 2010 [9].
The primary endpoint was HBV reactivation, defined as: (1) reappearance of HBV DNA, and (2) more than one or two log elevations of serum HBV DNA from the baseline level [7,12,13].

2.3. Data Extraction and Quality Assessment

Data extraction and quality assessment were conducted by two authors (JJY and SBA), independently. Full-text materials were examined independently following the screening of titles and abstracts. Discrepancies between authors were resolved by consensus or consultation with a third author (DAP or DWJ). To assess the risk of bias, we utilized the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS) tool (Cochrane Bias Method group, version 2.0). Further information on the outcome of the risk of bias is presented in the Supplementary Materials.

2.4. Statistical Analysis

The meta-analysis was performed using a random-effects model or fixed-effects model and presented pooled odds ratios (OR) and 95% confidence intervals (CI). Heterogeneity was visually checked using a forest plot and determined based on the Cochrane Q statistic (p < 0.10) and I2 statistics (≥50%). Subgroup analysis was used to explain the heterogeneity among the studies. Subgroup analysis was conducted by study area, baseline HBV DNA level, and HBV prophylaxis. We also estimated the pooled OR for HBV reactivation in resolved HBV infected patients. If possible (more than ten articles included in the analysis), a method using funnel plot and Egger’s test or AS-Thompsom’s test was performed to identify publication bias. The meta-analysis was performed using the RevMan software (version 5.3, Cochrane library) and R statistical software (version 4.1.1, The R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was considered at p < 0.05.

3. Results

3.1. Baseline Characteristics of Included Studies

This systematic review identified a total of 13,185 records (Figure 1). After eliminating duplicates, 2803 records were screened for titles and abstracts, and 50 articles from the reference lists were selected for full-text review. Finally, 39 studies were included in the quantitative analysis. These studies included 1673 patients with HBV/HCV co-infection in 35 articles and 13,497 resolved HBV (HBsAg-negative, anti-HBc-positive) patients in 27 studies (Table 1). Of the 39 studies, 12 (30.7%) studies were retrospective cohorts, and 26 (66.6%) studies were prospective studies from Europe (Italy, Germany, Spain, Poland, Portugal), Asia (Japan, China, Taiwan, Korea, Pakistan), and North America (United States). All included articles were published between 2015 and 2020.

3.2. DAA-Associated HBV Reactivation in HBsAg (+) Patients

In the 35 studies that reported data on HBsAg-positive patients receiving DAA therapy, the pooled HBV reactivation rate was 12% (95% confidence interval (CI) 6–19). Significant heterogeneity was observed among the studies (I2 = 87%). A forest plot of the meta-analysis is shown in Figure 2.

3.3. Subgroup Analysis

Subgroup analyses were performed according to the study location (east or west), baseline HBV DNA levels, and administration of prophylactic anti-HBV treatment. There were 35 studies that identified the origin of the research, 15 studies from the east, and 20 from the west. The pooled HBV reactivation rate was significant in both areas, and eastern studies showed a higher reactivation rate (17%) than Western studies (11%) (Supplementary Figure S1).
The risk of HBV reactivation was further analyzed in 16 studies that reported the baseline HBV DNA levels. Undetectable HBV DNA was defined as an HBV DNA level < 20 IU/mL. Patients with undetectable HBV DNA showed a decreased risk of reactivation than those with detectable HBV DNA (≥20 IU/mL) (OR 0.27, 95% CI 0.07–1.01, I2 = 0%) (Figure 3).
The risk of HBV reactivation was compared between patients who received prophylactic anti-HBV therapy and those who did not in seven studies. Although the pooled risk was lower in patients receiving prophylactic HBV therapy, statistical significance was not reached (OR 0.27, 95% CI 0.07–1.01, I2 = 0%) (Figure 4). There was no evidence of heterogeneity (I2 = 0%, p = 0.96). Due to the homogeneity of the studies, a fixed-effects model was employed, and the pooled risk was significantly lower for those who received prophylactic HBV therapy (OR 0.25, 95% CI 0.07–0.92).

3.4. DAA-Associated HBV Reactivation in Resolved HBV Patients

Most pooled studies of HBsAg-negative and HBcAb-positive patients receiving DAAs reported that there was no HBV reactivation. However, 5 of the 27 articles demonstrated reactivation. In the meta-analysis, the pooled reactivation risk was 0.4% in patients with resolved HBV (95% CI 0.002–0.01, I2 = 66.6%)

3.5. Risk of Bias

In the Supplementary Figures S1–S3, the risk of bias is shown. Excepting participant selection, the majority of categories exhibited a minimal risk of bias (Supplementary Figure S2).

4. Discussion

The present meta-analysis demonstrated a significant incidence of HBV reactivation in patients with HCV/HBV co-infection who were treated with DAA (12%). The risk factors for HBV reactivation were detectable baseline HBV DNA levels and the absence of HBV prophylaxis, indicating that HBV suppression prior to DAA therapy may prevent HBV reactivation. In contrast, the probability of HBV reactivation was minimal (0.4%) in patients with a resolved HBV infection.
Several systematic reviews have evaluated the risk of HBV reactivation in patients with HBV/HCV co-infection receiving antiviral HCV treatment [10,52,53,54]. The reported rate of HBV reactivation was 12.2% to 24.0% in patients with HBsAg positivity, and 0.1% to 1.4% in those with resolved HBV infection. Although the findings were in line with those of our study, these studies were limited by the sample size and type of HCV therapy. The study population was relatively small (n = 148–425), and two of the four systematic reviews only focused on patients receiving interferon (IFN)-based treatment rather than DAA therapy. Furthermore, subgroup analysis according to baseline HBV DNA level or the administration of pre-emptive antiviral therapy was not performed. In the present study, we thoroughly reviewed the literature and included studies using DAA rather than IFN-based treatment based on the inclusion criteria. We included a sufficient number of studies (35 studies with HBsAg-positive patients (n = 1673) and 27 studies with resolved HBV patients (n = 13,497)) published between 2015 and 2020 and performed a detailed subgroup analysis. Based on a large study population and recently published articles, we found that the risk of HBV reactivation was significant, especially in patients with detectable HBV DNA levels. Patients in these circumstances should be closely monitored, and preventive antiviral HBV therapy may be beneficial. Additionally, more attention is required for HBV reactivation when employing DAA therapy in the eastern region.
It is well known that the suppressed immune system induced by cytotoxic chemotherapy or immunosuppressants accelerates HBV reactivation in patients with a chronic or previous history of HBV infection [13]. Interestingly, the side effects of the DAA therapy were similar. Although this needs to be elucidated, several plausible mechanisms for this exist. First, the direct inhibitory mechanism of HCV was eliminated by DAA. In vitro studies have shown that HCV core protein (NS2 and NS5a) has an inhibitory effect on HBV replication [55,56] by suppressing HBV enhancer 1 [34] or the HBx protein [57]. In addition, it has been suggested that these two viruses compete for a limited replicative space [58]. Second, innate and/or adaptive immune responses may explain the indirect mechanisms [4]. HCV infection activates the host immune system. Pattern recognition receptors, including retinoic acid-inducible gene I and toll-like receptor 3, activate various immune response pathways, such as IFN and NF-kB [59], resulting in cytokine production and the subsequent overexpression of antiviral IFN-stimulated genes [60]. HCV may evade immune responses by mutation or signal transduction disruption, but these responses may suppress HBV. Therefore, treating HCV infection would lead to the loss of HBV suppression, which might result in reactivation.
Whether HBV reactivation is associated with baseline HBV DNA levels before DAA treatment is still controversial. In this study, we discovered that patients with detectable HBV DNA levels had a greater risk of reactivation than those with lower HBV DNA levels. In contrast, two systematic reviews showed that reactivation risk was similar between patients with undetectable HBV DNA and those with detectable HBV DNA. However, these studies reported that HBV reactivation-related hepatitis was significantly lower in patients with undetectable HBV DNA. Therefore, HBV DNA levels should be monitored before and during the DAA therapy.
Pre-emptive nucleos(t) ide (NUCs) treatment is recommended in patients with moderate (1–10%) to high-risk (≥10%) HBV reactivation undergoing cytotoxic chemotherapy or rituximab [12]. In the present study, the preventive effect of prophylactic NUCs was insignificant when the random-effects model was used. However, since the heterogeneity across studies was minimal, the fixed-effects model could be used for analysis. We discovered that preemptive HBV therapy significantly inhibited HBV reactivation. This discrepancy might be due to the small number of studies that were assessed (seven studies) and the fact that various NUCs (low- and high-genetic barrier NUCs) were analyzed rather than a single NUC. Since prophylactic NUCs therapy lowers mortality in patients with HBV reactivation, we believe that patients with detectable HBV DNA or impaired liver function prone to hepatitis require empirical antiviral therapy. Further studies are required to clarify these hypotheses.
The rate of HBV reactivation was negligible in patients with previous HBV infection (0.4%). Several studies have identified the risk factors associated with reactivation in these patients. Guo et al. reported that elevated liver enzyme levels might be associated with a risk of HBV reactivation in patients with resolved HBV [61]. On the other hand, retrospective and prospective studies have demonstrated that negative (<10 mIU/mL) or low anti-HBsAb (<100 mIU/mL) at baseline is a significant predictive factor for HBV reactivation [62,63,64]. Although the incidence of HBV reactivation is low, HBV DNA levels should be monitored throughout DAA therapy in resolved HBV patients, especially in those with risk factors.
This study has several limitations. First, there was significant heterogeneity among the analyzed studies. Various DAA regimens and HCV genotypes were the main sources of heterogeneity. Second, the definition of HBV reactivation varied among studies. We allowed for individual definitions of HBV reactivation because the definition varied among societies and changed over time. For instance, the 2015 American Gastroenterological Association guidelines defined HBV reactivation as de novo detectable HBV DNA if the baseline level was undetectable or a 10-fold increase in HBV DNA levels if the baseline level was detectable [13]. The European Association for the Study of the Liver guidelines published in 2016 defined an increase in viral load to >2000 IU/mL in conjunction with an increase in ALT [7]. However, according to the 2018 American Association of the Study of Liver Disease guidelines, HBV reactivation in HBsAg-positive patients is characterized as one of the following: (1) more than 2-log (100-fold) increase in HBV DNA over the baseline; (2) HBV DNA more than 3-log (1000) IU/mL in a patient with previously undetectable HBV DNA; (3) HBV DNA more than 4-log (10,000) IU/mL if the baseline level is unavailable [12]. Since the analyzed studies were published between 2015 and 2020, we chose a liberal definition of a 1–2-log increase in HBV DNA. Finally, further studies are warranted to elucidate the clinical utility, safety, and cost-effectiveness of prophylactic HBV antiviral prophylaxis.

5. Conclusions

The present study demonstrated a significant risk of HBV reactivation in patients with HBV/HCV co-infection undergoing DAA treatment. This meta-analysis indicated that co-infected patients should be closely monitored for the development of HBV reactivation and be considered to initiate HBV prevention before initiating DAAs.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jpm12121957/s1, Figure S1: The risk of HBV reactivation by area, Figure S2: Risk of bias, Figure S3: Funnel plot for analysis publication bias; Table S1: Search strategy and results.

Author Contributions

Conceptualization, D.A.P., S.B.A. and D.W.J.; methodology, D.A.P., M.J.K., S.B.A. and D.W.J.; software, J.H.O. and S.B.A.; validation, S.Y.Y. and J.-H.A.; formal analysis, D.A.P., M.J.K., S.Y.Y. and S.B.A.; investigation, J.H.O., J.-J.Y. and S.B.A.; resources, D.A.P.; data curation, D.A.P., M.J.K. and S.Y.Y.; writing—original draft preparation, J.H.O.; writing—review and editing, S.B.A. and D.W.J.; visualization, J.-J.Y., J.-H.A. and S.B.A.; supervision, D.A.P. and D.W.J.; project administration, S.Y.Y. and J.-H.A.; funding acquisition, S.Y.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the National Research Foundation of Korea (2020R1A2C2009227).

Informed Consent Statement

Not applicable.

Data Availability Statement

Clinical trial number: PROSPERO (International Prospective Register of Systematic Reviews), CRD42021241245.

Acknowledgments

This research was supported by National Evidence-based Healthcare Collaborating Agency (NECA) (N20-001).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Stanaway, J.D.; Flaxman, A.D.; Naghavi, M.; Fitzmaurice, C.; Vos, T.; Abubakar, I.; Abu-Raddad, L.J.; Assadi, R.; Bhala, N.; Cowie, B.; et al. The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. Lancet 2016, 388, 1081–1088. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin. Mol. Hepatol. 2019, 25, 93–159. [Google Scholar] [CrossRef] [Green Version]
  3. Donato, F.; Boffetta, P.; Puoti, M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer 1998, 75, 347–354. [Google Scholar] [CrossRef]
  4. Bellecave, P.; Gouttenoire, J.; Gajer, M.; Brass, V.; Koutsoudakis, G.; Blum, H.E.; Bartenschlager, R.; Nassal, M.; Moradpour, D. Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference. Hepatology 2009, 50, 46–55. [Google Scholar] [CrossRef] [PubMed]
  5. Chu, C.J.; Lee, S.D. Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment. J. Gastroenterol. Hepatol. 2008, 23, 512–520. [Google Scholar] [CrossRef]
  6. Bini, E.J.; Perumalswami, P.V. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions. Hepatology 2010, 51, 759–766. [Google Scholar] [CrossRef]
  7. European Association for the Study of the Liver (EASL). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017, 67, 370–398. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Yeh, M.L.; Huang, C.F.; Huang, C.I.; Holmes, J.A.; Hsieh, M.H.; Tsai, Y.S.; Liang, P.C.; Tsai, P.C.; Hsieh, M.Y.; Lin, Z.Y.; et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J. Hepatol. 2020, 73, 62–71. [Google Scholar] [CrossRef] [Green Version]
  9. Bersoff-Matcha, S.J.; Cao, K.; Jason, M.; Ajao, A.; Jones, S.C.; Meyer, T.; Brinker, A. Hepatitis B Virus Reactivation Associated with Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann. Intern. Med. 2017, 166, 792–798. [Google Scholar] [CrossRef] [PubMed]
  10. Chen, G.; Wang, C.; Chen, J.; Ji, D.; Wang, Y.; Wu, V.; Karlberg, J.; Lau, G. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology 2017, 66, 13–26. [Google Scholar] [CrossRef] [PubMed]
  11. Cheng, P.N.; Liu, C.J.; Chen, C.Y.; Tseng, K.C.; Lo, C.C.; Peng, C.Y.; Lin, C.L.; Chiu, H.C.; Chiu, Y.C.; Chen, P.J. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial. Clin. Gastroenterol. Hepatol. 2021, 166, 792–798. [Google Scholar] [CrossRef]
  12. Terrault, N.A.; Lok, A.S.F.; McMahon, B.J.; Chang, K.M.; Hwang, J.P.; Jonas, M.M.; Brown, R.S., Jr.; Bzowej, N.H.; Wong, J.B. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018, 67, 1560–1599. [Google Scholar] [CrossRef] [Green Version]
  13. Reddy, K.R.; Beavers, K.L.; Hammond, S.P.; Lim, J.K.; Falck-Ytter, Y.T. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015, 148, 215–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Wahle, R.C.; de Mello Perez, R.; Takemi Emori, C.; de Oliveira Uehara, S.N.; da Silva Fucuta, P.; Melo Rocha, C.; de Castro Amaral Feldner, A.C.; de Souza, E.S.I.S.; Carvalho-Filho, R.J.; Silva, A.E.; et al. Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis? Ann. Hepatol. 2015, 14, 317–324. [Google Scholar] [CrossRef]
  15. Gane, E.J.; Hyland, R.H.; An, D.; Svarovskaia, E.S.; Brainard, D.; McHutchison, J.G. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antivir. Ther. 2016, 21, 605–609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Abstracts of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan. Hepatol. Int. 2016, 10 (Suppl. 1), 1–506. [CrossRef] [PubMed]
  17. Sulkowski, M.S.; Chuang, W.L.; Kao, J.H.; Yang, J.C.; Gao, B.; Brainard, D.M.; Han, K.H.; Gane, E. No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. Clin. Infect. Dis 2016, 63, 1202–1204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Kim, J.-h.; Choe, W.H. S-148 HBV reactivation in a HBV/HCV-coinfected patient after daclatasvir and asunaprevir treatment. Korean Assoc. Intern. Med. Fall Conf. 2016, 2016, 123. [Google Scholar]
  19. Londoño, M.C.; Lens, S.; Mariño, Z.; Bonacci, M.; Ariza, X.; Broquetas, T.; Pla, A.; Bartres, C.; Adriani, M.V.; Rodríguez-Tajes, S.; et al. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Aliment. Pharm. 2017, 45, 1156–1161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Kawagishi, N.; Suda, G.; Onozawa, M.; Kimura, M.; Maehara, O.; Ohara, M.; Izumi, T.; Umemura, M.; Ito, J.; Nakai, M.; et al. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J. Viral Hepat. 2017, 24, 1098–1106. [Google Scholar] [CrossRef]
  21. Wang, C.; Ji, D.; Chen, J.; Shao, Q.; Li, B.; Liu, J.; Wu, V.; Wong, A.; Wang, Y.; Zhang, X.; et al. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas among Patients with Hepatitis C Treated with Direct-acting Antiviral Agents. Clin. Gastroenterol. Hepatol. 2017, 15, 132–136. [Google Scholar] [CrossRef] [PubMed]
  22. Tamori, A.; Abiru, S.; Enomoto, H.; Kioka, K.; Korenaga, M.; Tani, J.; Enomoto, M.; Sugiyama, M.; Masaki, T.; Kawada, N.; et al. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy. J. Viral Hepat. 2018, 25, 608–611. [Google Scholar] [CrossRef] [PubMed]
  23. Coppola, N.; Stanzione, M.; Messina, V.; D’Adamo, G.; Sangiovanni, V.; Fontanella, L.; De Pascalis, S.; Stornaiuolo, G.; Macera, M.; Piai, G. DAA-based regimens in HBsAg/anti-HCV positive patients: The need to control HBV replication to avoid HBV reactivation. J. Hepatol. 2017, 1, S727. [Google Scholar] [CrossRef]
  24. Ancha, A.; Modi, A.A. Risk of HBV Reactivation with DAA Therapy for HCV in those with evidence of Past HBV Exposure. Hepatology 2017, 66, 620A. [Google Scholar]
  25. Hayashi, K.; Ishigami, M.; Ishizu, Y.; Kuzuya, T.; Honda, T.; Hirooka, Y.; Goto, H. The impact of hepatitis B virus infection on sustained virologic response and HBV reactivation in patients with chronic hepatitis C who treated by all-oral direct-acting antivirals regimens. Gastroenterology 2017, 152, S1092–S1093. [Google Scholar] [CrossRef]
  26. Yeh, M.L.; Huang, C.F.; Hsieh, M.H.; Ko, Y.M.; Chen, K.Y.; Liu, T.W.; Lin, Y.H.; Liang, P.C.; Hsieh, M.Y.; Lin, Z.Y. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J. Gastroenterol. Hepatol. 2017, 32, 1754–1762. [Google Scholar] [CrossRef] [PubMed]
  27. Liu, C.H.; Liu, C.J.; Su, T.H.; Fang, Y.J.; Yang, H.C.; Chen, P.J.; Chen, D.S.; Kao, J.H. Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. Open Forum Infect. Dis. 2017, 4, ofx028. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Doi, A.; Sakamori, R.; Tahata, Y.; Urabe, A.; Morishita, N.; Yamada, R.; Furuta, K.; Kodama, T.; Hikita, H.; Yakushijin, T. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol. Res. 2017, 47, 1438–1444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Ogawa, E.; Furusyo, N.; Murata, M.; Toyoda, K.; Hayashi, T.; Ura, K. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV. Liver Int. 2018, 38, 76–83. [Google Scholar] [CrossRef]
  30. Mücke, V.; Mücke, M.; Peiffer, K.H.; Weiler, N.; Welzel, T.; Sarrazin, C.; Zeuzem, S.; Berger, A.; Vermehren, J. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Aliment. Pharmacol. Ther. 2017, 46, 432–439. [Google Scholar] [CrossRef]
  31. Loggi, E.; Gitto, S.; Galli, S.; Minichiello, M.; Conti, F.; Grandini, E.; Scuteri, A.; Vitale, G.; Di Donato, R.; Cursaro, C. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J. Clin. Virol. 2017, 93, 66–70. [Google Scholar] [CrossRef] [PubMed]
  32. Macera, M.; Stanzione, M.; Messina, V.; D’Adamo, G.; Sangiovanni, V.; Mioglioresi, L.; Fontanella, L.; De Pascalis, S.; Stornaiuolo, G.; Lanza, A.G. Interferon-free regimens in hepatitis B surface antigen/anti–hepatitis C virus positive patients: The need to control hepatitis B virus replication to avoid hepatitis B virus reactivation. Clin. Gastroenterol. Hepatol. 2017, 15, 1800–1802. [Google Scholar] [CrossRef] [PubMed]
  33. Belperio, P.S.; Shahoumian, T.A.; Mole, L.A.; Backus, L.I. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology 2017, 66, 27–36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Tang, L.; Tolaymat, M.; Stonesifer, E.; Kottilil, S.; Wilson, E. Absence of hepatitis B reactivation among veterans with serological evidence of previous hepatitis B infection receiving anti-hepatitis C direct acting antivirals. J. Hepatol. 2017, 1, S251–S252. [Google Scholar] [CrossRef]
  35. Calvaruso, V.; Ferraro, D.; Licata, A.; Bavetta, M.G.; Petta, S.; Bronte, F.; Colomba, G.; Craxì, A.; Di Marco, V. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J. Viral Hepat. 2018, 25, 72–79. [Google Scholar] [CrossRef]
  36. Yanny, B.; Sahota, A. Reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir (LDV/SOF) for hepatitis C virus infection in a community based setting. Gastroenterology 2017, 152, S1059. [Google Scholar] [CrossRef]
  37. Preda, C.; Popescu, C.; Baicus, C.; Constantinescu, I.; Oproiu, A.; Voiosu, T.; Diculescu, M.; Negreanu, L.; Gheorghe, L.; Sporea, I. Risk of hepatitis B virus reactivation in hepatitis B virus+ hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r+ dasabuvir+ ribavirin. J. Viral Hepat. 2018, 25, 834–841. [Google Scholar] [CrossRef]
  38. Butt, A.A.; Yan, P.; Shaikh, O.S.; Abou-Samra, A.B. Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: Results from ERCHIVES. Aliment. Pharmacol. Ther. 2018, 47, 412–420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Lee, S.W.; Lee, T.Y.; Yang, S.S.; Peng, Y.C.; Yeh, H.Z.; Chang, C.S. Prevalence of Hepatitis B Reactivation among Chinese Individuals with Chronic Hepatitis C Treated with Pan-Oral Direct-Acting Antivirals. Gastroenterol. Res. 2018, 11, 124–129. [Google Scholar] [CrossRef] [Green Version]
  40. Woo, H.Y.; Park, Y.J.; Heo, J. The Risk of HBV Reactivation among HBV/HCV Co-Infected Patients Treated with Direct-Acting Antiviral Agents: A Single Center Experience; EASL: Geneva, Switzerland, 2019. [Google Scholar]
  41. D’Ambrosio, R.; Degasperi, E.; Aghemo, A.; Borghi, M.; Perbellini, R.; De Nicola, S.; Lunghi, G.; Lampertico, P. Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: A single-center experience. Dig. Liver Dis. 2018, 50, 41. [Google Scholar] [CrossRef]
  42. Figueiredo, L.; Alexandrino, G.; Costa, M.; Carvalho, R.; Alberto, S.; Martins, A. Reactivation of Hepatitis B Virus Infection during Treatment of Hepatitis C with Direct-Acting Antivirals; United European Gastroenterology: Vienna, Austria, 2018. [Google Scholar]
  43. Liu, C.-J.; Chuang, W.-L.; Sheen, I.-S.; Wang, H.-Y.; Chen, C.-Y.; Tseng, K.-C.; Chang, T.-T.; Massetto, B.; Yang, J.C.; Yun, C. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology 2018, 154, 989–997. [Google Scholar] [CrossRef] [Green Version]
  44. Ahmed, A.; Elantouny, N.; Zidan, A.; Sadek, A.; Elrasad, M. Effect of treatment of hepatitis C by directly acting antivirals on chronic hepatitis C and B co-infected patients. Sci. Rep. 2018, 8, 1661. [Google Scholar] [CrossRef]
  45. Mücke, M.M.; Mücke, V.T.; Peiffer, K.H.; Sarrazin, C.; Zeuzem, S.; Berger, A.; Vermehren, J. Absence of HBV Reactivation in Patients with Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study. Open Forum Infect. Dis. 2019, 6, ofy340. [Google Scholar] [CrossRef]
  46. Osman, H.A.; Ghweil, A.A.; Sabry, A.M.; Mahdy, R.E.; Khodeary, A. Management of patients with hepatitis B virus reactivation post–DAA treatment of chronic hepatitis C virus infection in HCV–HBV coinfected patients with pretreatment HBeAg seroconversion and early degree of hepatic fibrosis. Infect. Drug Resist. 2019, 12, 3067. [Google Scholar] [CrossRef] [Green Version]
  47. Gutiérrez García, M.L.; Manzano Alonso, M.L.; Ferrer Rosique, J.; Muñoz Gómez, R.; Alonso López, S.; Fernández Álvarez, I.; Fernández Rodríguez, C.M. Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents. Rev. Esp. Enferm. Dig. 2019, 111, 129–133. [Google Scholar] [CrossRef] [PubMed]
  48. Tahir, M.; Ravikumar, N.P.G.; Chathura, W.; Martinez, A. 1024 A Retrospective Analysis of Hepatitis-B Reactivation in Hepatitis-C Patients Treated with Direct-Acting Antivirals Therapy. Am. J. Gastroenterol. 2019, 114, S587. [Google Scholar] [CrossRef]
  49. Nagaty, A.; Helmy, S.H.; Abd El-Wahab, E.W. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt. Trans. R. Soc. Trop. Med. Hyg. 2020, 114, 200–212. [Google Scholar] [CrossRef] [PubMed]
  50. Jaroszewicz, J.; Pawłowska, M.; Simon, K.; Zarębska-Michaluk, D.; Lorenc, B.; Klapaczyński, J.; Tudrujek-Zdunek, M.; Sitko, M.; Mazur, W.; Janczewska, E. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Rev. Anti-Infect. Ther. 2020, 18, 1045–1054. [Google Scholar] [CrossRef]
  51. Xu, Q.; Zhang, W.; Ma, Y.X.; He, C.N.; Zhang, L.T.; Abulitifu, Y.; Li, Y.; Wang, N.; Wang, H.L.; Zhao, Y.Y.; et al. Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: A real-world multicenter clinical study. Zhonghua Gan Zang Bing Za Zhi 2021, 29, 1046–1052. [Google Scholar]
  52. Jiang, X.W.; Ye, J.Z.; Li, Y.T.; Li, L.J. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J. Gastroenterol. 2018, 24, 3181–3191. [Google Scholar] [CrossRef]
  53. El Kassas, M.; Shimakawa, Y.; Ali-Eldin, Z.; Funk, A.L.; Wifi, M.N.; Zaky, S.; El-Raey, F.; Esmat, G.; Fontanet, A. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver Int. 2018, 38, 2159–2169. [Google Scholar] [CrossRef] [PubMed]
  54. Mücke, M.M.; Backus, L.I.; Mücke, V.T.; Coppola, N.; Preda, C.M.; Yeh, M.L.; Tang, L.S.Y.; Belperio, P.S.; Wilson, E.M.; Yu, M.L.; et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2018, 3, 172–180. [Google Scholar] [CrossRef]
  55. Shih, C.M.; Lo, S.J.; Miyamura, T.; Chen, S.Y.; Lee, Y.H. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J. Virol. 1993, 67, 5823–5832. [Google Scholar] [CrossRef] [PubMed]
  56. Shih, C.M.; Chen, C.M.; Chen, S.Y.; Lee, Y.H. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J. Virol. 1995, 69, 1160–1171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Schüttler, C.G.; Fiedler, N.; Schmidt, K.; Repp, R.; Gerlich, W.H.; Schaefer, S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J. Hepatol. 2002, 37, 855–862. [Google Scholar] [CrossRef] [PubMed]
  58. Chen, S.Y.; Kao, C.F.; Chen, C.M.; Shih, C.M.; Hsu, M.J.; Chao, C.H.; Wang, S.H.; You, L.R.; Lee, Y.H. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J. Biol. Chem. 2003, 278, 591–607. [Google Scholar] [CrossRef] [Green Version]
  59. Holmes, J.A.; Yu, M.L.; Chung, R.T. Hepatitis B reactivation during or after direct acting antiviral therapy—Implication for susceptible individuals. Expert Opin. Drug Saf. 2017, 16, 651–672. [Google Scholar] [CrossRef]
  60. Takeuchi, O.; Akira, S. Innate immunity to virus infection. Immunol. Rev. 2009, 227, 75–86. [Google Scholar] [CrossRef]
  61. Guo, L.; Wang, D.; Ouyang, X.; Tang, N.; Chen, X.; Zhang, Y.; Zhu, H.; Li, X. Recent Advances in HBV Reactivation Research. Biomed. Res. Int. 2018, 2018, 2931402. [Google Scholar] [CrossRef]
  62. Seto, W.K.; Chan, T.S.; Hwang, Y.Y.; Wong, D.K.; Fung, J.; Liu, K.S.; Gill, H.; Lam, Y.F.; Lie, A.K.; Lai, C.L.; et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: A prospective study. J. Clin. Oncol. 2014, 32, 3736–3743. [Google Scholar] [CrossRef]
  63. Kusumoto, S.; Tanaka, Y.; Suzuki, R.; Watanabe, T.; Nakata, M.; Takasaki, H.; Fukushima, N.; Fukushima, T.; Moriuchi, Y.; Itoh, K.; et al. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study. Clin. Infect. Dis. 2015, 61, 719–729. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Nishida, T.; Hiramatsu, N.; Mizuki, M.; Nagatomo, I.; Kida, H.; Tazumi, K.; Shinzaki, S.; Miyazaki, M.; Yakushijin, T.; Tatsumi, T.; et al. Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic. Hepatol. Res. 2013, 43, 339–346. [Google Scholar] [CrossRef] [PubMed]
Jpm 12 01957 g001 550
Figure 1. Literature search process for the systematic review and meta-analysis.
Figure 1. Literature search process for the systematic review and meta-analysis.
Jpm 12 01957 g001
Jpm 12 01957 g002 550
Figure 2. Overall risk of HBV reactivation.
Figure 2. Overall risk of HBV reactivation.
Jpm 12 01957 g002
Jpm 12 01957 g003 550
Figure 3. The risk of HBV reactivation according to baseline HBV DNA.
Figure 3. The risk of HBV reactivation according to baseline HBV DNA.
Jpm 12 01957 g003
Jpm 12 01957 g004 550
Figure 4. The risk of HBV reactivation according to prophylactic anti-HBV therapy.
Figure 4. The risk of HBV reactivation according to prophylactic anti-HBV therapy.
Jpm 12 01957 g004
Table
Table 1. Characteristics of studies in the final analysis (n = 39).
Table 1. Characteristics of studies in the final analysis (n = 39).
Author, YearCountryStudy DesignPopulationHBsAg(+) PopulationHBsAg(−), Anti-HBc(+) PopulationGenotypeDAA
Wahle 2015 [14]BrazilRetrospective10100NADAA
Gane 2016 [15]USAProspective88NA1LDV/SOF
Wang 2016 [16]ChinaProspective35510 1,2,3,6SOF + DCV/LDV + SOF/OMB + PTR + DAS
Sulkowski 2016 [17]Taiwan/KoreaProspective1780103NALDV + SOF
Kim 2017 [18]KoreaProspective82113NANADAA
Londono 2017 [19]SpainProspective35210641,2,3,4OBV/PTV ± DSV ± RBV
LDV/SOF ± RBV
DCV/SOF ± RBV
SOF + RBV
DCV/SMV
Kawagishi 2017 [20]JapanRetrospective851821,2LDV/SOF
DCV/ASV
SOF + RBV
Wang 2017 [21]ChinaProspective327101241,2LDV/SOF, DCV/SOF, OBV/PTV + DSV
Tamori 2017 [22]JapanProspective160257651,2LDV/SOF
DCV/ASV
OMB/PTR
SOF + RBV
Coppola 2017 [23]ItalyProspective16160NADAA
Ancha 2017 [24]USARetrospective9410188NADAA
Hayashi 2017 [25]JapanRetrospective2561780NADAA
Yeh 2017 [26]TaiwanProspective64757NALDV/SOF ± RBV, SOF + RBV, OMB/PrOD
Liu 2017 [27]TaiwanProspective9312811,2LDV/SOF, LDV/SOF + RBV, SOF + RBV, PrOD, PrOD+RBV
Doi 2017 [28]JapanProspective4614751,2DAA
Ogawa 2017 [29]JapanRetrospective1832631,2LDV, SOF
Mucke 2017 [30]GermanyProspective84892721,2,3,4LDV, SOF RBV, OBV/PTV + DSV RBV, DCV, SOF + RBV
Loggi 2017 [31]ItalyProspective1372421,2,3,4SOF ± RBV, SOF + LDV ± RBV, SOF + SMV ± RBV, PrOD ± RBV
Macera 2017 [32]ItalyProspective29290NADAA
Belperio 2017 [33]USARetrospective622903777295NADAA
Tang 2017 [34]UnknownUnknown1920 NALDV/SOF, PrOD, SOF/VEL, GZR/EBR
Calvaruso 2018 [35]ItalyRetrospective1048371,2,3,4LDV/SOF ± RBV
DCV/SOF + RBV
SMV/SOF + RBV
OBV/PTV/DSV + RBV
SOF + RBV
Yanny 2018 [36]USARetrospective2831561271,4LDV + SOF
Preda 2018 [37]RomaniaProspective207015NA1OBV/PTV/DSV + RBV
Butt 2018 [38]USARetrospectiveDAA:34632, PEG:23475DAA group:3322, PEG:1751DAA:9343, PEG:5005NASOF/SMV, SOF/LDV,
PrOD, SOF/RBV
Lee 2018 [39]TaiwanRetrospective15311531,2SOF + LDV, PrOD, DCV + ASV
Park 2018 [40]KoreaRetrospective6262NANAIFN: 34, DAA:24
D’Ambrosio 2018 [41]ItalyProspective692103011DAA
Figueiredo 2018 [42]PortugalProspective3292123NADAA
Wang 2018 [16]ChinaProspective11111101,2LDV/SOF
Liu 2018 [43]TaiwanProspective11111001,2LDV + SOF
Ahmed 2019 [44]EgyptProspective201620NASOF + DAC + RBV: SOF + DAC:7, SOF + SIM:5
Mucke 2019 [45]GermanyProspective82292631,2,3,4LDV, SOF ± RBV, OBV/PTV + RBV,
OBV/PTV+DSV ± RBV, SMV, SOF ± RBV,
DCV, SOF ± RBV,SOF + RBV
Osman 2019 [46]EgyptProspective140140 NASOF + DCV
GutierrezGarcia 2019 [47]SpainProspective13377356NADAA
Tahir 2019 [48]PakistanRetrospective260051NADAA
Nagaty 2020 [49]EgyptProspective287338NASOF + DCV,
SOF + DCV + RBV
Jaroszewicz 2020 [50]PolandRetrospective1015211112391,3,4OBV/PTV/RBV ± DSV ± RBV, SOF, GZR/EBR ± RBV
Xu 2020 [51]ChinaProspective1131201,2,3SOF/VEL
Abbreviations: NA, not available; RCT, randomized controlled trial; SOF, Sofosbuvir; RBV or r, Ribavirin; SMV, Simeprevir; DCV, Daclatasvir; LDV, Ledipasvir; GLE, Glecaprevir; PIB, Pibrentasvir; EBR, Elbasvir; GZR, Grazoprevir; PrOD, paritaprevir/ritonavir with ombitasvir and dasabuvir; OMB, Ombitasvir; PTR, Paritaprevir; r, ritonavir; DAS, Dasabuvir; ASV, Asunaprevir; VEL, Velpatasvir.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Oh, J.H.; Park, D.A.; Ko, M.J.; Yoo, J.-J.; Yim, S.Y.; Ahn, J.-H.; Jun, D.W.; Ahn, S.B. Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis. J. Pers. Med. 2022, 12, 1957. https://doi.org/10.3390/jpm12121957

AMA Style

Oh JH, Park DA, Ko MJ, Yoo J-J, Yim SY, Ahn J-H, Jun DW, Ahn SB. Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine. 2022; 12(12):1957. https://doi.org/10.3390/jpm12121957

Chicago/Turabian Style

Oh, Joo Hyun, Dong Ah Park, Min Jung Ko, Jeong-Ju Yoo, Sun Young Yim, Ji-Hyun Ahn, Dae Won Jun, and Sang Bong Ahn. 2022. "Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis" Journal of Personalized Medicine 12, no. 12: 1957. https://doi.org/10.3390/jpm12121957

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop